Final development and commercial preparation of Phactory™, a universal platform technology to enable scalable phagebased drug development and productionbroad
Phactory · Horizon Europe grant · 2025-07-01–2027-06-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2024-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2024-ACCELERATOROPEN-01. CORDIS record →
Objective
The rise of drug-resistant bacteria necessitates the development of alternative therapies that can specifically target and eliminate these pathogens while minimizing harm to the patient's microbiome. Bacteriophages (phages) are potent therapeutics that can fight multidrugresistant pathogenic bacteria. Unlike broad-spectrum antibiotics, phages can selectively eliminate bacteria. However, the current production processes for phages pose considerable biosafety concerns and are often relatively inefficient, unreliable, and unscalable. Invitris has fundamentally transformed the way phages can be developed with its unique in vitro platform technology, Phactory™. For the first time, Phactory™ enables scalable, personalized production and rapid engineering of novel drugs based on phages. We aim to leverage the support by EIC to standardize the clinical production process of Phactory™ and conduct clinical trials to validate the efficacy and safety of novel phage-based therapies.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| INVITRIS | DE | coordinator | €2,499,999 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.